South San Francisco, United States
Akero Therapeutics is a clinical-stage company focused on developing groundbreaking treatments for patients with serious metabolic diseases, particularly MASH, where there is a high unmet medical need. The company's lead product candidate, EFX, is currently undergoing evaluation in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), along with three ongoing Phase 3 clinical trials. These trials include patients with pre-cirrhotic MASH or compensated cirrhosis due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program is built upon the results of two Phase 2b clinical trials, namely the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4). Akero Therapeutics was founded in 2017 and is headquartered in South San Francisco.
The company received a significant Post-IPO Equity investment on 05 March 2024.
Akero Therapeutics operates within the Biotechnology, Health and Wellness, and Life Sciences industries.
